JP2009504192A - ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 - Google Patents

ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 Download PDF

Info

Publication number
JP2009504192A
JP2009504192A JP2008527196A JP2008527196A JP2009504192A JP 2009504192 A JP2009504192 A JP 2009504192A JP 2008527196 A JP2008527196 A JP 2008527196A JP 2008527196 A JP2008527196 A JP 2008527196A JP 2009504192 A JP2009504192 A JP 2009504192A
Authority
JP
Japan
Prior art keywords
nucleic acid
nucleotide sequence
rrna
molecule
rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008527196A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009504192A5 (OSRAM
Inventor
デニス ドライジン
エミル マイケロッティ
シーン オーブリエン
ウィリアム ジー． ライス
アダム シディキ−ジャイン
ジェフリー ピー． ホイッテン
Original Assignee
サイリーン ファーマシューティカルズ インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイリーン ファーマシューティカルズ インコーポレーティッド filed Critical サイリーン ファーマシューティカルズ インコーポレーティッド
Publication of JP2009504192A publication Critical patent/JP2009504192A/ja
Publication of JP2009504192A5 publication Critical patent/JP2009504192A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3511—Conjugate intercalating or cleaving agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2008527196A 2005-08-19 2006-08-18 ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用 Pending JP2009504192A (ja)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70959805P 2005-08-19 2005-08-19
US73246005P 2005-11-01 2005-11-01
US75159305P 2005-12-19 2005-12-19
US77592406P 2006-02-22 2006-02-22
US77932706P 2006-03-02 2006-03-02
US78380106P 2006-03-16 2006-03-16
US78910906P 2006-04-03 2006-04-03
PCT/US2006/032508 WO2007022474A2 (en) 2005-08-19 2006-08-18 HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF

Publications (2)

Publication Number Publication Date
JP2009504192A true JP2009504192A (ja) 2009-02-05
JP2009504192A5 JP2009504192A5 (OSRAM) 2009-10-01

Family

ID=37758472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008527196A Pending JP2009504192A (ja) 2005-08-19 2006-08-18 ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用

Country Status (5)

Country Link
US (2) US20070117770A1 (OSRAM)
EP (1) EP1926372A2 (OSRAM)
JP (1) JP2009504192A (OSRAM)
CA (1) CA2619663A1 (OSRAM)
WO (1) WO2007022474A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532123A (ja) * 2009-06-29 2012-12-13 アプタバイオ セラピュティックス インコーポレイテッド 治療効能のある変形核酸及びグアノシンを含有するオリゴヌクレオチド変形体

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100063046A1 (en) * 2006-05-17 2010-03-11 Whitten Jeffrey P Tetracyclic imidazole analogs
US8278057B2 (en) * 2007-09-14 2012-10-02 Nestec S.A. Addressable antibody arrays and methods of use
PL2214491T3 (pl) * 2007-10-05 2016-11-30 Analogi chinolonów i związane z nimi sposoby
WO2009135388A1 (en) * 2008-05-09 2009-11-12 Zhiping Liu A molecule detecting system
JP5768282B2 (ja) * 2008-12-10 2015-08-26 ユニヴァーシティ オブ ワシントン ｒＲＮＡ前駆体のレシオメトリック分析
EP2430159A1 (en) * 2009-05-15 2012-03-21 Boehringer Ingelheim International GmbH Improved cell lines having reduced expression of nocr and use thereof
US20140086839A1 (en) * 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
US20190290593A1 (en) 2016-04-29 2019-09-26 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
KR20200131251A (ko) 2018-02-15 2020-11-23 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이의 염, 조성물, 및 이들의 사용 방법
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2023025161A1 (zh) * 2021-08-23 2023-03-02 北京嘉树佳业科技有限公司 来源于药用植物的sRNA及其应用
WO2025114459A1 (en) * 2023-11-28 2025-06-05 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688645A (en) * 1983-01-10 1997-11-18 Gen-Probe Incorporated Method for detecting, identifying, and quantitating non-viral organisms
US5723597A (en) * 1983-01-10 1998-03-03 Gen-Probe Incorporated Ribosomal nucleic acid probes for detecting organisms or groups of organisms
US5681698A (en) * 1991-04-25 1997-10-28 Gen-Probe Incorporated 23S rRNA nucleic acid probes to mycobacterium kansasii
ES2163512T3 (es) * 1994-06-14 2002-02-01 Dainippon Pharmaceutical Co Nuevo compuesto, procedimiento para producirlo, y agente antitumoral.
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6930084B1 (en) * 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
AU744873B2 (en) * 1996-11-06 2002-03-07 Regents Of The University Of California, The Isolated tumor necrosis factor receptor releasing enzyme, compositions comprising the enzyme and methods of the use thereof
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US7138384B1 (en) * 1997-08-29 2006-11-21 The Regents Of The University Of California Modulators of DNA cytosine-5 methyltransferase and methods for use thereof
AU2657499A (en) * 1998-02-04 1999-08-23 Board Of Regents, The University Of Texas System Synthesis of quinobenzoxazine analogues with topoisomerase ii and quadruplex interactions for use as antineoplastic agents
US6911314B2 (en) * 1999-05-14 2005-06-28 The Regents Of The University Of California Screening for drugs that affect TNF receptor releasing enzyme
US20030204075A9 (en) * 1999-08-09 2003-10-30 The Snp Consortium Identification and mapping of single nucleotide polymorphisms in the human genome
US20020076721A1 (en) * 2000-08-07 2002-06-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of pancreatic cancer
US20030166213A1 (en) * 2000-12-15 2003-09-04 Greenspan Ralph J. Methods for identifying compounds that modulate disorders related to nitric oxide/ cGMP-dependent protein kinase signaling
US6645749B2 (en) * 2001-05-25 2003-11-11 Novozymes A/S Lipolytic enzyme
AU2003226304A1 (en) * 2002-04-05 2003-10-27 Cylene Pharmaceuticals, Inc. Methods for targeting quadruplex dna
US7001588B2 (en) * 2002-09-12 2006-02-21 Cylene Pharmaceuticals Expanded porphyrin compositions for tumor inhibition
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US20040115706A1 (en) * 2003-09-11 2004-06-17 Jin Cheng He High-throughput methods for identifying quadruplex forming nucleic acids and modulators thereof
ES2358267T3 (es) * 2004-03-15 2011-05-09 Sunesis Pharmaceuticals, Inc. Composición farmacéutica que comprende sns-595 y sus usos.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532123A (ja) * 2009-06-29 2012-12-13 アプタバイオ セラピュティックス インコーポレイテッド 治療効能のある変形核酸及びグアノシンを含有するオリゴヌクレオチド変形体

Also Published As

Publication number Publication date
WO2007022474B1 (en) 2008-02-14
US20070117770A1 (en) 2007-05-24
US20090181377A1 (en) 2009-07-16
EP1926372A2 (en) 2008-06-04
CA2619663A1 (en) 2007-02-22
WO2007022474A2 (en) 2007-02-22
WO2007022474A3 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
JP2009504192A (ja) ヒトリボソームＤＮＡ（ｒＤＮＡ）およびリボソームＲＮＡ（ｒＲＮＡ）核酸ならびにそれらの使用
Kettle et al. Potent and selective inhibitors of MTH1 probe its role in cancer cell survival
Liu et al. New disubstituted quindoline derivatives inhibiting Burkitt’s lymphoma cell proliferation by impeding c-MYC transcription
US11964971B2 (en) Methods and compositions for modulating splicing
US20220048902A1 (en) Methods and compositions for modulating splicing
An et al. Dynamic regulation of a metabolic multi-enzyme complex by protein kinase CK2
KR20210151823A (ko) 비정상적인 스플라이싱을 보정하기 위한 조성물 및 방법
JP6968054B2 (ja) Ｐｄｅ３ａまたはｓｌｆｎ１２を発現するがんのための組成物および方法
US9023787B2 (en) MAPKAP kinase-2 as a specific target for blocking proliferation of P53-defective
EP3084446A1 (en) Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US20090181468A1 (en) Methods and compositions for treating cellular proliferative diseases
US20180201606A1 (en) Method of inhibiting dyrk1b
US20090291437A1 (en) Methods for targeting quadruplex sequences
KR20210123344A (ko) 스플라이싱을 조절하는 방법 및 조성물
EP3665482A1 (en) Targeting kinases for the treatment of cancer metastasis
Wang et al. Differential effects of camptothecin derivatives on topoisomerase I-mediated DNA structure modification
WO2017217796A1 (ko) Rhoa 억제제 및 이의 용도
Verga et al. Polyheteroaryl oxazole/pyridine-based compounds selected in vitro as G-quadruplex ligands inhibit rock kinase and exhibit antiproliferative activity
Wang et al. Novel phenanthrene imidazoles as telomeric G-quadruplex ligands trigger potent immunogenic cell death in triple-negative breast cancer
Mandi et al. Cleavage of abasic sites in DNA by an aminoquinoxaline compound: augmented cytotoxicity and DNA damage in combination with an anticancer drug chlorambucil in Human colorectal carcinoma cells
JP2021521831A (ja) Ｒｎａへのヌクレアーゼの小分子による標的指向動員
JP2015502137A (ja) Ｅ１酵素変異体およびその用途
US20060141529A1 (en) Compositions, kits and assays containing reagents directed to cortactin and an ARG/ABL protein kinase
Tarashima et al. Synthesis of a cyclic dinucleotide analogue with ambiguous bases, 5-aminoimidazole-4-carboxamide
US20230302139A1 (en) Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090817

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20090817

A072 Dismissal of procedure [no reply to invitation to correct request for examination]

Free format text: JAPANESE INTERMEDIATE CODE: A073

Effective date: 20101220